Revolutionary Treatment Targeting Progressive Multiple Sclerosis
Overview of Progressive Multiple Sclerosis
Progressive Multiple Sclerosis (p-MS) is a challenging condition characterized by a gradual worsening of neurological function. Unlike relapsing forms of MS, patients with p-MS experience persistent progression without distinct relapses.
Research Initiative by Rutgers Health
Rutgers Health researchers have launched a clinical trial to explore an engineered immune cell therapy aimed at stopping p-MS progression. This therapy uses modified cells designed to target the underlying autoimmune mechanisms.
Eligibility for Participation
- Patients diagnosed with primary or secondary progressive MS.
- Age range of participants should be between 18 and 65 years.
- Willingness to comply with all study protocols.
Potential Impact of the Treatment
This revolutionary treatment could significantly alter the landscape of therapeutic options for patients suffering from progressive multiple sclerosis, offering new hope where few effective therapies exist.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.